Published in Virchows Arch on February 25, 2016
Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. Int J Mol Sci (2016) 0.88
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? J Immunother Cancer (2016) 0.84
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol (2016) 0.84
Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy. Oncoimmunology (2016) 0.80
What does PD-L1 positive or negative mean? J Exp Med (2016) 0.79
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. Int J Mol Sci (2017) 0.78
PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1(+) and CD8(+) tumor-infiltrating T cells and outcome. Mod Pathol (2016) 0.77
PD-L1 Expression in Pancreatic Cancer. J Natl Cancer Inst (2017) 0.77
Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget (2016) 0.76
PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology (2017) 0.75
Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma. Oncotarget (2017) 0.75
Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. Onco Targets Ther (2017) 0.75
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. Oncotarget (2017) 0.75
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Curr Oncol Rep (2017) 0.75
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS One (2017) 0.75
PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. Oncotarget (2017) 0.75
Immunogenomics: using genomics to personalize cancer immunotherapy. Virchows Arch (2017) 0.75
Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro. Cancer Gene Ther (2017) 0.75
Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: what's next? J Thorac Dis (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 24.87
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 16.91
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest (2013) 4.96
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res (2004) 4.65
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst (2013) 3.63
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A (2008) 2.99
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol (2016) 2.79
ALK in lung cancer: past, present, and future. J Clin Oncol (2013) 2.70
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2014) 2.67
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther (2015) 2.21
Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer (2012) 1.93
PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer (2015) 1.85
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer (2014) 1.83
Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration. JAMA Oncol (2016) 1.69
Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer (2010) 1.68
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest (2015) 1.67
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev (2014) 1.56
PD-1/PD-L1 inhibitors. Curr Opin Pharmacol (2015) 1.53
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac Oncol (2015) 1.48
European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol (2015) 1.47
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res (2013) 1.46
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov (2015) 1.28
Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res (2015) 1.18
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol (2015) 1.15
Quantitative analysis of tumor in bronchial biopsy specimens. J Thorac Oncol (2010) 1.12
PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol (2015) 1.06
Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol (2015) 1.03
The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res (2014) 1.03
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol (2014) 0.98
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol (2013) 0.97
Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res (2015) 0.97
PD-L1 Expression as a Predictive Biomarker: Is Absence of Proof the Same as Proof of Absence? JAMA Oncol (2016) 0.94
Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. Expert Rev Mol Diagn (2015) 0.90
PD-L1 expression in small cell lung cancer. Eur J Cancer (2015) 0.87
PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development. JAMA Oncol (2016) 0.81
[The accreditation of a surgical pathology and somatic genetic laboratory (LPCE, CHU of Nice) according to the ISO 15189 norm: Sharing of experience]. Ann Pathol (2013) 0.76
Pitfalls in lung cancer molecular pathology: how to limit them in routine practice? Curr Med Chem (2012) 0.76
Addressing the unmet need in lung cancer: The potential of immuno-oncology. Cancer Treat Rev (2015) 0.76
[Immunohistochemistry and personalised medicine in lung oncology: advantages and limitations]. Bull Cancer (2014) 0.75